Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rigel Pharmaceuticals has begun enrolling patients in a Phase I study to evaluate the safety and tolerability of R348 as a potential treatment for patients with rheumatoid arthritis, psoriasis and other immune disorders.
Subscribe to our email newsletter
This study will evaluate the safety and pharmacokinetics of R348 in young, healthy males using a double-blind, placebo-controlled, single dose and multiple rising doses of R348. Results are expected in mid-2008.
Donald Payan, executive vice president and chief scientific officer at Rigel, said: “R348 enters the clinic at a time when Rigel’s product portfolio is demonstrating its potential contribution to the field of immunology. With R348 targeting T-cells and our oral syk kinase inhibitor, R788, targeting B-cells and other immune cells, Rigel has mounted a comprehensive assault on autoimmune disorders.”